Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.
Tonix Pharmaceuticals Holding Corp. develops and commercializes biotechnology products for central nervous system disorders, immunology, infectious diseases and rare diseases. Company news centers on TONMYA, an FDA-approved cyclobenzaprine HCl sublingual tablet for fibromyalgia in adults, along with marketed acute migraine products Zembrace SymTouch and Tosymra.
Recurring updates also cover Tonix’s development pipeline, including TNX-4800, a long-acting anti-Borrelia OspA human monoclonal antibody for Lyme disease prophylaxis; TNX-1900 intranasal potentiated oxytocin for craniofacial pain conditions; TNX-1700 and TNX-4700 immuno-oncology programs; TNX-801 vaccine research; and TNX-1500 for prevention of kidney transplant rejection. Other company developments include scientific presentations, clinical and preclinical data, commercial access arrangements, operating results, capital-structure disclosures and governance matters.
Tonix Pharmaceuticals (Nasdaq: TNXP) communicates significant findings regarding its experimental vaccines based on horsepox. Published in Genome Biology, researchers reported a 99.7% genomic identity between a 1860 smallpox vaccine and horsepox, suggesting historical use of horsepox as a safe smallpox vaccine. Tonix's TNX-801, a horsepox-based live virus vaccine, aims to prevent smallpox and monkeypox, while TNX-1800, also derived from horsepox, targets COVID-19 by eliciting T cell responses. These findings enhance the understanding of vaccine development and efficacy.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that all eight non-human primates vaccinated with TNX-1800, a modified horsepox virus COVID-19 vaccine candidate, developed neutralizing antibodies and manifested a skin reaction known as 'take', indicating a strong T cell immune response. The study showed TNX-1800's safety and its potential as a single-dose vaccine, which could simplify distribution. The company plans to advance to human Phase 1 trials in 2021, with manufacturing support from FUJIFILM Diosynth Biotechnologies. Preliminary results suggest TNX-1800 could provide long-term immunity against COVID-19.
Tonix Pharmaceuticals (Nasdaq: TNXP) is addressing the increasing placebo responses in PTSD drug trials, which complicate the effectiveness of treatments. CEO Seth Lederman presented a new statistical method, RHNPCOT, at the Neuropsychiatric Drug Development Summit, showing improved analytics for the Phase 3 HONOR study of TNX-102 SL. The company plans a Phase 3 study in Kenya targeting police, expected to begin in Q3 2021. Tonix is also preparing to unblind data from the RECOVERY study by year-end, which may validate the new method.
Tonix Pharmaceuticals (NASDAQ:TNXP) will participate in the 2020 Fall Investor Summit from November 16-18. This virtual event will feature 75 companies and over 300 investors, creating a platform for networking and investment opportunities.
Tonix is focused on developing treatments for human diseases, particularly in the central nervous system and immunology fields. Their lead vaccine candidate, TNX-1800, aims to protect against COVID-19, with data expected in 4Q'20. Additionally, their CNS candidate, TNX-102 SL, is in Phase 3 trials for fibromyalgia, with results anticipated later this year.
Tonix Pharmaceuticals (Nasdaq: TNXP) has announced that its CEO, Seth Lederman, is set to present at three virtual investor conferences this November. The details of the events are as follows:
- Virtual Fall Investor Summit: November 16, 2020, at 1:30 p.m. ET
- Sidoti Virtual Microcap Conference: November 19, 2020, at 8:30 a.m. ET
- A.G.P Virtual Healthcare Symposium: November 19, 2020, featuring a panel on COVID-19 vaccines.
Webcasts will be available on the company's website post-event.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will speak at the 3rd Annual Neuropsychiatric Drug Development Summit, virtually held from November 10-12, 2020. Dr. Lederman's presentation is set for November 12 at 11:55 a.m. ET, focusing on developing a PTSD therapeutic in Phase 3 clinical development. An archived replay of the presentation will be available on the company's website after the event. The summit aims to address challenges in developing neuropsychiatric drugs, spotlighting innovations in clinical trial design and treatment options.
Tonix Pharmaceuticals (Nasdaq: TNXP) reported Q3 2020 financial results, highlighting a net loss of $12 million, or $0.09 per share, up from a $7.8 million loss in Q3 2019. The company has $55.7 million in cash and equivalents, a significant increase from $11.2 million at the end of 2019. Key developments include advancing its COVID-19 vaccine candidate TNX-1800, with data from animal studies expected by year-end 2020, and a Phase 1 human study anticipated in 2021. Tonix is also progressing with other potential therapies and expansion in Massachusetts.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has initiated the PRECISION study to analyze immune responses to COVID-19. This observational study focuses on individuals who have recovered from COVID-19 or were asymptomatic, aiming to develop human monoclonal antibody therapeutics and identify biomarkers for protective immunity. The results are anticipated in the first half of 2021. Tonix's lead vaccine candidate, TNX-1800, aims to generate durable T cell immunity and may enhance participant selection for clinical trials. Data from this study is expected to inform future COVID-19 vaccine development.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that President and CEO Seth Lederman will present at the 2020 BIO Investor Forum Digital from October 13-15, 2020. The presentation will be available on demand for registered participants. Tonix focuses on developing therapeutics for CNS and immunology, including the COVID-19 vaccine candidate TNX-1800 and TNX-102 SL for fibromyalgia. Expected data from animal studies and Phase 3 trials are anticipated in Q4 2020 and the second half of 2021, respectively. More details can be found at tonixpharma.com.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a live webinar on September 24, 2020, at 10:00 a.m. ET, focusing on antibody versus T cell immune responses and vaccine development challenges. The event features experts from IAVI, Merck, and Tonix, moderated by Clive Cookson of the Financial Times. Participants include Swati Gupta (IAVI), Seth Lederman (CEO, Tonix), and Gokul Swaminathan (Merck). An archived recording will be available on Tonix's investor website. Tonix's lead vaccine candidate is TNX-1800, targeting COVID-19.